UNSPSC 51401708: Olanzapine embonate

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7S6Q4MHCB. European Medicines Agency schedules Olanzapine embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32279. Olanzapine embonate generally arises in the molecular formula C23H16O6.C17H20N4S.H2O. The term 'olanzapine embonate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule olanzapine embonate under HS 29349990 and SITC 51579.

SMILES: CC1CC2C(S1)NC3CCCCC3N=C2N4CCN(CC4)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51401708 Olanzapine embonate is a Commodity code that nominally designates a specific antipsychotic pharmaceutical product, but the recent state and local opportunities tagged under it diverge significantly from that scope—the posted solicitations cover naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution rather than olanzapine specifically. The actual buying activity under this code spans health departments and cooperative purchasing alliances seeking naloxone and drug deactivation systems for community health programs, state health and human services commissions evaluating manufacturer direct-contracting models to optimize pharmacy benefit administration, and multi-state purchasing cooperatives soliciting generic pharmaceuticals and OTC products for distribution through authorized wholesale channels. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing organizations serving state and local government facilities.

Recent activity appears concentrated in Florida and Minnesota, with ancillary engagement from Texas HHS and Oregon through the Minnesota Multistate Cooperative Purchasing Alliance. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct contracts outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and awarded agreements effective July 1, 2026. The MMCAP RFP requires vendors to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., and emphasizes price competitiveness weighted at 75 percent of evaluation, with a mandatory 3 percent administrative fee structure.